Confounding Effects of Benign Lung Diseases on Non-Small Cell Lung Cancer Serum Biomarker Discovery

Rathinam, Sridhar; Alzetani, Aiman; Starczynski, Jane; Rajesh, P.; Nyangoma, Stephen; Wakelam, Michael J.O.; James, Nicholas D.; Wei, Wenbin; Billingham, Lucinda; Johnson, Philip J.; Martin, Ashley; Ward, Douglas G.

doi:10.1007/s12014-009-9033-4

Cited by 2 publications

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serum samples were taken at several time points, as part of the CLUB (Carcinoma of the Lung Biomarkers) study, a prospective study of potential lung cancer biomarkers that has been described previously [15]. The current project was a substudy and only those with pre-operative samples remaining were selected.…”

Section: Prognostic Effect Of Serum Markers Of the Vitamin D Axismentioning

confidence: 99%

Circulating DBP level and prognosis in operated lung cancer: an exploration of pathophysiology

Turner¹,

McGowan²,

Millen³

et al. 2012

Eur Respir J

View full text Add to dashboard Cite

Vitamin D stimulates transcription of antiangiogenic and apoptotic factors that may suppress tumours, while vitamin D binding protein (DBP) may be a biomarker in murine lung cancer models. We sought to ascertain whether the vitamin D axis is altered in lung cancer or influences prognosis.148 lung cancer patients, 68 other intrathoracic cancer patients and 33 noncancer controls were studied for up to 5 yrs. Circulating DBP and vitamin D levels were compared between groups and their effect on survival assessed by Cox regression analysis. Expression of DBP and vitamin D receptor (VDR) was examined in lung cancer cell lines and in normal and tumour lung tissue by Western blot and immunohistochemistry.Low serum DBP levels predicted lung cancer-specific death (p50.04), and DBP was poorly expressed in lung cancer cells on Western blot and immunohistochemistry. Vitamin D did not predict cancer survival and VDR expression was variable in tumours.Preservation of serum DBP is a significant independent factor associated with better cancer outcome in operated lung cancer patients. Given the established role of DBP in macrophage activation and clearance of abnormal cells, further study on its involvement in lung cancer is merited.

show abstract

Section: Prognostic Effect Of Serum Markers Of the Vitamin D Axismentioning

confidence: 99%

Circulating DBP level and prognosis in operated lung cancer: an exploration of pathophysiology

Turner¹,

McGowan²,

Millen³

et al. 2012

Eur Respir J

View full text Add to dashboard Cite

show abstract

Proteomic analysis of resectable non-small cell lung cancer: post-resection serum samples may be useful in identifying potential markers

Rathinam

Ward

James

et al. 2011

Interact CardioVasc Thorac Surg

View full text Add to dashboard Cite

Surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry (SELDI-TOF-MS) can be used to analyse peptides and proteins in clinical samples. A prospective study was undertaken on patients undergoing curative resection for non-small cell lung cancer (NSCLC): we used SELDI-TOF-MS to compare the proteomic profiles of serum from these patients both before surgical resection and after resection (disease-free) to identify potential biomarkers. Student t-tests were used, and a P-value of <0.01 was considered significant. Twenty-five patients with NSCLC [76% male, mean age 69 (range 53-81) years] were analysed. There were 13 squamous cell carcinomas, 10 adenocarcinomas and 2 large cell carcinomas with a stage distribution of four stage IA, 11 stage IB, five stage IIB, three stage IIIA, one stage IIIB and one stage IV. SELDI spectra generated with immobilised metal affinity chromatography arrays produced 170 peaks. Of these, 35 showed significant differences in their intensities between the preoperative and post-resection states (P<0.01). Postoperative samples in the disease-free state may represent good controls to identify biomarkers in NSCLC, avoiding the difficulties associated with cross-sectional studies. These pilot data need to be validated with larger numbers of patients.

show abstract

Confounding Effects of Benign Lung Diseases on Non-Small Cell Lung Cancer Serum Biomarker Discovery

Cited by 2 publications

References 32 publications

Circulating DBP level and prognosis in operated lung cancer: an exploration of pathophysiology

Circulating DBP level and prognosis in operated lung cancer: an exploration of pathophysiology

Proteomic analysis of resectable non-small cell lung cancer: post-resection serum samples may be useful in identifying potential markers

Contact Info

Product

Resources

About